Muscle-specific kinase B-cell receptor and DNA (MuSK BCR/DNA)

This target entry is a composite description typically associated with therapeutic strategies for Muscle-Specific Kinase (MuSK) Myasthenia Gravis, an autoimmune disorder where patients produce antibodies against MuSK at the neuromuscular junction (PMID: 31243143). The first component, the Anti-MuSK B-cell receptor, is a highly specific target for Chimeric Autoantibody Receptor (CAAR) T-cell therapies, such as MuSK-CAART, which are designed to selectively bind and kill only the B-cells expressing receptors for MuSK while sparing healthy B-cells (PMID: 31243143, ClinicalTrials.gov: NCT04422912). The second component, broad DNA in proliferating lymphocytes, refers to the mechanism of traditional immunosuppressive agents like cyclophosphamide or mycophenolate, which disrupt DNA replication to prevent the expansion of all activated lymphocytes. This combination entry likely reflects a clinical protocol or a multi-pronged pharmacological approach aimed at both the precision depletion of autoantibody-producing cells and the broad suppression of the inflammatory immune environment.

Other names

Anti-MuSK B-cell receptorMuSK-specific B-cell receptorDNA in proliferating lymphocytesMuscle-specific tyrosine kinase receptor (MuSK) B-cell receptor

The target represents a dual approach: specific elimination of pathogenic B-cells via Chimeric Autoantibody Receptor (CAAR) T-cells that recognize the anti-MuSK B-cell receptor, and non-specific suppression of lymphocyte proliferation through the inhibition of DNA synthesis or induction of DNA damage.